Obesity pillarsSep 29, 2025

Using Nutrition Approaches with GLP-1 Therapies: Challenges and Possible Solutions

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jan 2, 2026

Abstract

Delivering optimal nutrition management to people with obesity treated with GLP-1 based therapies presents healthcare providers with many challenges.

Patients on GLP-1 therapies often struggle with maintaining weight reduction due to inadequate nutrition advice.
Weight reduction associated with GLP-1 therapies may lead to muscle mass loss and increase the risk of sarcopenic obesity.
Comprehensive lifestyle counselling should include recommendations for adequate nutrition, with a focus on increased protein intake and resistance training.
Addressing mental health, sleep hygiene, and physical activity is crucial for effective management of obesity in these patients.
Evidence-based nutrition guidelines can help ensure consistent and scientifically supported advice for healthcare professionals.

Simplified

BACKGROUND: Obesity is a heterogeneous systemic chronic disease associated with excess adiposity and a complex etiology and is increasing in prevalence worldwide. Initially used to treat type 2 diabetes mellitus, glucagon-like peptide-1 (GLP-1) based therapies are now widely prescribed for individuals with overweight and obesity as an adjunct to a reduced-calorie diet and increased physical activity. However, despite their impressive weight reduction capabilities, many patients on GLP-1 based therapies do not receive appropriate nutrition advice and struggle to maintain their weight reduction.

METHODS: This narrative review explores and summarizes existing literature on the challenges associated with nutrition intake in people with obesity taking GLP-1 based therapies and practical applications of nutrition and lifestyle interventions for the management of these individuals to ensure their best long-term health outcomes.

RESULTS: Delivering optimal nutrition management to people with obesity treated with GLP-1 based therapies presents healthcare providers with many challenges including addressing the impact of obesity and weight reduction on body composition (particularly muscle mass loss and risk of sarcopenic obesity), and poor nutrition. Physicians should work with dietitians and other healthcare providers to deliver comprehensive lifestyle counselling that is patient-centered, aligning with the needs and preferences of the individual. This should include advice on: timely and appropriate nutrition that centers on adequate macronutrient, micronutrient and fluid intake, particularly increased protein intake alongside resistance training for the preservation of muscle mass; mental health; sleep hygiene, physical activity; and medication adherence and persistence. Evidence-based nutrition guidelines can also provide an important framework for healthcare professionals, helping to ensure nutrition advice is consistent and based on rigorous scientific research.

CONCLUSIONS: Our findings underscore the importance of ensuring that patients treated with GLP-1 based therapies are closely monitored and provided with comprehensive nutrition and lifestyle support to ensure they achieve the best long-term health outcomes.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

Dr Angela Fitch has served on advisory boards for Vivus, Currax, Eli Lilly, Novo Nordisk, Sidekick Health, Seca, and is a speaker for Eli Lilly, Novo Nordisk and Rhythm Pharmaceuticals. Linda Gigliotti has served on an expert panel on GLP-1 and nutrition for Nestlé Health Science and as a consultant for Amgen. Dr. Harold Bays’ research site institution has received research grants from 89Bio, Abbvie, Allergan, Alon Medtech/Epitomee, Aligos, Altimmune, Amgen, Anji Pharma, AstraZeneca, Bioage, Biohaven, Bionime, Boehringer Ingelheim, Carmot, Chorus/Bioage, Eli Lilly, Esperion, Evidera, Fractyl, GlaxoSmithKline, Graviton, HighTide, Home Access, Horizon, Ionis, Kallyope, LG-Chem, Marea, Madrigal, Merck, Mineralys, New Amsterdam, Novartis, NovoNordisk, Pfizer, Regeneron, Satsuma, Selecta, Shionogi, Skye/Birdrock, TIMI, Veru, Viking, Vivus, Zomagen. Dr. Harold Bays has served as a consultant (e.g., executive/national committee member, protocol/drug development advisor, and/or expert panel) for 89Bio, Altimmune, Amgen, Boehringer Ingelheim, Eva Pharma, Kiniksa, HighTide, Lilly, Nestle, Novo Nordisk, Regeneron, Rivus, Veru, Zomagen, ZyVersa.

PubMed

Using Nutrition Approaches with GLP-1 Therapies: Challenges and Possible Solutions

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief